Dr. Abhilash Moolupuri presented the initial exploratory and phase I/II results of a trial evaluating a novel PSMA-targeting ...

This study, presented at SNMMI 2025, aimed to further evaluate the safety profile and determine the optimal therapeutic dose of 177 Lu-P17-088, while also exploring its preliminary efficacy in the ...

In one patient, total body scans were performed at 15 minutes, 1 hour, 2 hours, and 4 hours post-injection. The effective dose was 0.022 mSv/MBq, with the stomach wall receiving the highest organ dose ...

Pre-therapeutic PSMA PET/CT information can be used to predict 177 Lu-PSMA-617 therapy response patterns and outcomes, with various quantitative and visual methods proposed. This study, presented at ...

Dr. Kevin Leung presented an artificial intelligence-based risk score for the prognostic evaluation of prostate cancer patients using PSMA PET/CT imaging. Dr. Leung argued that improved survival ...

(UroToday.com) The 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in New Orleans, LA, was host to an Oncology Discovery and Translational session. Dr. Gary Ulaner ...

SNMMI annual meeting featured a radiotheranostics session and a presentation by Dr. Xuejen Wen discussing the development of PSMA targeting radioligand 161 Tb-LNC1011 for prostate cancer theranostics.

(UroToday.com) The 2025 SNMMI annual meeting featured a prostate cancer and dosimetry session and a presentation by Dr. Loic Djaileb discussing clinical protocols to monitor efficacy of 177 Lu-PSMA ...

(UroToday.com) The 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in New Orleans, LA, was host to an Oncology Discovery and Translational session. Dr. Huipan Liu ...

SNMMI annual meeting featured a prostate cancer session and a presentation by Dr. Sabina Dizdarevic discussing sequencing and combining beta and alpha targeted radionuclide treatments in the ...

(UroToday.com) The 2025 SNMMI annual meeting featured a prostate cancer and molecular imaging session and a presentation by Dr. Jiarou Wang discussing the first human study of 68 Ga-P17-079 in ...

The IMPACT-RCC study 7 evaluated visualization of clear cell RCC lesions in 42 patients with metastatic disease (n = 449 lesions). Patients in this study had a lesion size cutoff of 1 cm (lymph nodes ...